CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0769 (clinicaltrials.gov NCT No: NCT00866333)
Title:A PHASE 2 MULTI-CENTER STUDY OF ENTINOSTAT (SNDX-275) IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
Principal Investigator:Anas Younes
Treatment Agent:Entinostat; SNDX-275
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if entinostat can help to
control Hodgkin’s lymphoma. The safety of this drug will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Entinostat
SNDX-275
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Syndax Pharmaceuticals, Inc
Return Visit:Screening, Day 1 of every cycle, Day 8 of Cycle 1, Day 15 of every cycle, End
of Treatment and Followup
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Anas Younes
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults